Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity

References

• BerwickMErdeiEHayJMelanoma epidemiology and public healthDermatol Clin2009272205214viii19254665
   PubMed Web of Science ®Google Scholar
• AgarwalaSSO’DaySJCurrent and future adjuvant immunotherapies for melanoma: Blockade of cytotoxic T-lymphocyte antigen-4 as a novel approachCancer Treat Rev201137213314220638184
   PubMed Web of Science ®Google Scholar
• LensMBDawesMGlobal perspectives of contemporary epidemiological trends of cutaneous malignant melanomaBr J Dermatol2004150217918514996086
   PubMed Web of Science ®Google Scholar
• BalchMHReintgenDSKirkwoodJMHoughtonACutaneous melanomaDe VitaVTHellmanSRosenbergSACancer: Principles and Practice of Oncology5th edPhiladelphia, PAJB Lippincott1997
   Google Scholar
• SoengasMSLoweSWApoptosis and melanoma chemoresistanceOncogene200319;222031383151
   Web of Science ®Google Scholar
• FecherLACummingsSDKeefeMJAlaniRMToward a molecular classification of melanomaJ Clin Oncol200725121606162017443002
   PubMed Web of Science ®Google Scholar
• PostovitLMSeftorEASeftorREHendrixMJTargeting nodal in malignant melanoma cellsExpert Opin Ther Targets200711449750517373879
   PubMed Web of Science ®Google Scholar
• MarkovicSNEricksonLARaoRDMelanoma Study Group of Mayo Clinic Cancer CenterMalignant melanoma in the 21st century, part 2: staging, prognosis, and treatmentMayo Clin Proc200782449051317418079
   PubMed Web of Science ®Google Scholar
• La PortaCADrug resistance in melanoma: New perspectivesCurr Med Chem200714438739117305541
   PubMed Web of Science ®Google Scholar
• McNultySEdel RosarioRCenDMeyskensFLJrYangSComparative expression of NFkappaB proteins in melanocytes of normal skin vs benign intradermal naevus and human metastatic melanoma biopsiesPigment Cell Res200417217318015016307
   PubMedGoogle Scholar
• ChenJWuHHanDXieCUsing anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancerCancer Lett2006231216917516399221
   PubMed Web of Science ®Google Scholar
• LiJLWangLLiuXYIn vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticlesCancer Lett2009274231932618977071
   PubMed Web of Science ®Google Scholar
• ChoKWangXNieSChenZGShinDMTherapeutic nanoparticles for drug delivery in cancerClin Cancer Res20081451310131618316549
   PubMed Web of Science ®Google Scholar
• GrefRMinamitakeYPeracchiaMTTrubetskoyVTorchilinVLangerRBiodegradable long-circulating polymeric nanospheresScience19942635153160016038128245
   PubMed Web of Science ®Google Scholar
• ZhangQZZhaLSZhangYThe brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in ratsJ Drug Target200614528129016882548
   PubMed Web of Science ®Google Scholar
• DongYFengSSMethoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugsBiomaterials200425142843284914962562
   PubMed Web of Science ®Google Scholar
• LuWZhangYTanYZHuKLJiangXGFuSKCationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain deliveryJ Control Release2005107342844816176844
   PubMed Web of Science ®Google Scholar
• RapoportNPhysical stimuli-responsive polymeric micelles for anticancer drug deliveryProg Polym Sci200732962990
   Web of Science ®Google Scholar
• KimTYKimDWChungJYPhase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated pacli-taxel, in patients with advanced malignanciesClin Cancer Res200410113708371615173077
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRDrug delivery systems: Entering the mainstreamScience200430356651818182215031496
   PubMed Web of Science ®Google Scholar
• StaytonPSHoffmanASMurthyNMolecular engineering of proteins and polymers for targeting and intracellular delivery of therapeuticsJ Control Release2000651–220322010699281
   PubMed Web of Science ®Google Scholar
• WartlickHMichaelisKBalthasarSStrebhardtKKreuterJLangerKHighly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cellsJ Drug Target200412746147115621671
   PubMed Web of Science ®Google Scholar
• AnhornMGWagnerSKreuterJLangerKvon BriesenHSpecific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticlesBioconjug Chem200819122321233118937508
   PubMed Web of Science ®Google Scholar
• MitraAColemanTBorgmanMNanAGhandehariHLineBRPolymeric conjugates of mono- and bi-cyclic alpha Vbeta3 binding peptides for tumor targetingJ Control Release2006114217518316889865
   PubMed Web of Science ®Google Scholar
• XiongXBHuangYLuWLEnhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimeticJ Control Release2005107226227516125816
   PubMed Web of Science ®Google Scholar
• AdamsGPWeinerLMMonoclonal antibody therapy of cancerNat Biotechnol20052391147115716151408
   PubMed Web of Science ®Google Scholar
• WalczakHMillerREAriailKTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivoNat Med1999521571639930862
   PubMed Web of Science ®Google Scholar
• EvdokiouABouralexisSAtkinsGJChemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosisInt J Cancer200299449150411992538
   PubMed Web of Science ®Google Scholar
• LeBlancHNAshkenaziAApo2L/TRAIL and its death and decoy receptorsCell Death Differ2003101667512655296
   PubMed Web of Science ®Google Scholar
• ChuntharapaiADodgeKGrimmerKIsotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4J Immunol200116684891489811290766
   PubMed Web of Science ®Google Scholar
• IchikawaKLiuWZhaoLTumoricidal activity of a novel antihuman DR5 monoclonal antibody without hepatocyte cytotoxicityNat Med20017895496011479629
   PubMed Web of Science ®Google Scholar
• CretneyETakedaKSmythMJCancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathwayInt J Biochem Cell Biol200739228028617097329
   PubMed Web of Science ®Google Scholar
• GeorgakisGVLiYHumphreysRActivity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell deathBr J Haematol2005130450151016098063
   PubMed Web of Science ®Google Scholar
• LuWZhangYTanYZHuKLJiangXGFuSKCationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain deliveryJ Control Release2005107342844816176844
   PubMed Web of Science ®Google Scholar
• KocbekPObermajerNCegnarMKosJKristlJTargeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibodyJ Control Release20071201–2182617509712
   PubMed Web of Science ®Google Scholar
• WangHSongSKouGTreatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndromeCancer Immunol Immunother200756111775178317431617
   PubMed Web of Science ®Google Scholar
• BriggerIDubernetCCouvreurPNanoparticles in cancer therapy and diagnosisAdv Drug Deliv Rev200254563165112204596
   PubMed Web of Science ®Google Scholar
• MoYLimLYPreparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristateJ Control Release20051071304216051391
   PubMed Web of Science ®Google Scholar
• MouawadRSebertMMichelsJBlochJSpanoJPKhayatDTreatment for metastatic malignant melanoma: Old drugs and new strategiesCrit Rev Oncol Hematol2010741273919781957
   PubMed Web of Science ®Google Scholar
• QuirinCMainkaAHesseANettelbeckDMCombining adenoviral oncolysis with temozolomide improves cell killing of melanoma cellsInt J Cancer2007121122801280717724714
   PubMed Web of Science ®Google Scholar
• LillehammerTEngesaeterBOPrasmickaiteLMaelandsmoGMFodstadOEngebraatenOCombined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell linesJ Gene Med20079644045117410615
   PubMed Web of Science ®Google Scholar
• de BruynMBremerEHelfrichWAntibody-based fusion proteins to target death receptors in cancerCancer Lett152011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• MotokiKMoriEMatsumotoAEnhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2Clin Cancer Res2005113126313515837769
   PubMed Web of Science ®Google Scholar
• PukacLKanakarajPHumphreysRHGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBr J Cancer2005921430144115846298
   PubMed Web of Science ®Google Scholar
• DuikerEWMomCHde JongSThe clinical trail of TRAILEur J Cancer200642142233224016884904
   PubMed Web of Science ®Google Scholar
• ZhangXDFrancoAVNguyenTGrayCPHerseyPDifferential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cellsJ Immunol200016483961397010754286
   PubMed Web of Science ®Google Scholar
• NguyenTThomasWZhangXDGrayCHerseyPImmunologically- mediated tumour cell apoptosis: The role of TRAIL in T cell and cytokine-mediated responses to melanomaForum (Genova)200010324325211007932
   PubMedGoogle Scholar
• VisariaRKGriffinRJWilliamsBWEnhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha deliveryMol Cancer Ther2006541014102016648573
   PubMed Web of Science ®Google Scholar
• MamotCDrummondDCNobleCOEpidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivoCancer Res20056524116311163816357174
   PubMed Web of Science ®Google Scholar